The trascation allows BPTC to introduce Angel to new customers that require the advanced cell therapy development and cGMP manufacturing services.
The agreement will facilitate to expand Angel’s Cramlington facility by procuring both short and longer term contracts.
Angel Biotechnology COO Gordon Sherriff said they believe that BPTC will allow them to leverage the growing impetus of North American cell therapy companies to move their research into the clinic while faced with regulatory hurdles that are more manageable in the UK.
BioProcess Technology Consultants president and principal consultant Howard Levine said the need to manufacture these products in a fully cGMP compliant facility is to ensure treatments for patients as they progress through clinical development.